window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : May 4, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

CDMOs & Manufacturing

  • CDMOs & Manufacturing,Cell & Gene Therapy,Regulatory Affairs,Technology and platforms

    USP backs mass photometry for AAV analytics in gene therapy QC

    The US Pharmacopeia (USP) has recognized mass photometry as a [...]

    July 3, 2025
  • CDMOs & Manufacturing,Drug Development,Partnerships & Funding,Rare Diseases

    Shionogi and BioVersys agree €498M licensing deal for NTM drug candidates

    Deal gives Shionogi access to BioVersys’ BV500 program targeting serious [...]

    July 2, 2025
  • CDMOs & Manufacturing,Drug Development,Regulatory Affairs,Technology and platforms

    Thermo Fisher upgrades charged aerosol detection tech to improve complex drug analysis

    Thermo Fisher Scientific has introduced a new version of its [...]

    July 2, 2025
  • CDMOs & Manufacturing,Drug Delivery & Formulation,Patient Centricity

    Kindeva and Rocket Science Health partner to advance targeted intranasal delivery device

    Collaboration aims to support clinical development of platform designed to [...]

    July 1, 2025
  • CDMOs & Manufacturing,Cell & Gene Therapy,Oncology,Partnerships & Funding

    eXmoor and Signadori Bio partner to advance monocyte-based cell therapy for solid tumours

    New alliance focuses on translation, process development and GMP-readiness for [...]

    July 1, 2025
  • Artificial Intelligence,CDMOs & Manufacturing,Cell & Gene Therapy,Partnerships & Funding

    Unlocking collaboration: How data sharing and digital innovation are shaping the future of cell and gene therapy manufacturing

    The case for smarter collaboration in CGT manufacturing  As the [...]

    July 1, 2025
  • CDMOs & Manufacturing,Drug Development,Market Access & Commercialization,Partnerships & Funding,Technology and platforms

    Sphere Bio enters China market with Redbert Biotechnology distribution deal

    Sphere Bio has signed an exclusive distribution agreement with Redbert [...]

    June 27, 2025
  • Artificial Intelligence,CDMOs & Manufacturing,Drug Development,Technology and platforms

    AI can’t thrive in chaos: New survey finds labs still struggling with basics

    A new industry survey has revealed that while life sciences [...]

    June 27, 2025
  • CDMOs & Manufacturing,Cell & Gene Therapy,Drug Development,Oncology,Precision medicine,Technology and platforms

    Galapagos taps CELLforCURE by SEQENS to manufacture CAR-T therapy in France

    CELLforCURE by SEQENS has partnered with Galapagos to manufacture GLPG5101, [...]

    June 27, 2025
  • CDMOs & Manufacturing,Drug Development,Oncology,Technology and platforms

    Orano Med invests $5M to expand US radiopharma capabilities

    Orano Med has expanded its US research and development center [...]

    June 27, 2025
Previous111213Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Orano Med appoints Frederic Desdouits as CEO to advance targeted alpha therapy pipeline
    Categories: Biotech, Healthcare leadership, Movers & Shakers, Oncology, Pharmaceuticals and therapeutics, Research & Development
  • Aravax adds allergy specialists to board as peanut therapy advances
    Categories: Biotech, Clinical Development, Clinical Trials, Healthcare leadership, Immunology, Movers & Shakers
  • AI-derived drug candidate reduces fentanyl intake in preclinical opioid study
    Categories: Artificial Intelligence, Clinical studies, Drug discovery, Neurosciences, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top